Natco Pharma Ltd has achieved a significant milestone with the approval from the US health regulator for its generic version of Everolimus tablets for oral suspension. This approval marks a key step ...

The ANDA is held by its partner Natco Pharma Limited, India and Breckenridge plans to launch immediately. Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year ...

Everolimus plus lanreotide resulted in a progression-free survival of 29.7 months in patients with gastroenteropancreatic neuroendocrine tumors, compared with 11.5 months with everolimus monotherapy.